AUA Annual Meeting | Conference

Dr. Mohammed Haseebuddin on PD-1 Expression in RCC

August 17th 2016

Dr. Alexander I. Sankin on HHLA2 in Bladder Cancer

August 17th 2016

Dr. Neal Shore on Increasing Healthcare Costs and Metastasis Risk in Prostate Cancer

August 7th 2016

​Neal Shore, MD, medical director of the Carolina Urologic Research Institute, discusses a retrospective study investigating the relationship between treatment costs and the timing of diagnosis of metastases in prostate cancer.

Gyorgy Petrovics on Frequency of BRCA Mutations in African American Prostate Cancer Patients

August 2nd 2016

Gyorgy Petrovics, PhD, associate director, Center for Prostate Disease Research (CPDR), research associate professor in the department of surgery at the Uniformed Services University of the Health Sciences (USUHS), discusses BRCA1 and BRCA2 mutations in African American prostate cancer patients.

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

July 22nd 2016

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

July 11th 2016

Dr. Marc Bjurlin on Predictive Models for Prostate Cancer Risk

June 29th 2016

Dr. Stacy Loeb on Screening Considerations in Prostate Cancer

June 28th 2016

Dr. Gary Steinberg on New AUA Guidelines for Bladder Cancer

June 28th 2016

Dr. Rastinehad on Transperineal Fusion Biopsy for Prostate Cancer Focal Therapy

June 3rd 2016

Art Rastinehad, DO, Director of Focal Therapy and Interventional Urologic Oncology, Mount Sinai Health System, discusses an electromagnetically (EM) tracked transperineal MR/US fusion-guided biopsy platform (tpFBx) for prostate cancer.

Dr. Stanley Yap on Sequential Therapy for Muscle-Invasive Bladder Cancer

May 27th 2016

Stanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses sequential therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer.

Gene Expression Signature Predicts Hormonal Resistance in Prostate Cancer

May 24th 2016

Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.

High Genomic Classifier Score Increases Risk of Dying From Prostate Cancer

May 21st 2016

Results from a study using the Decipher Prostate Cancer Classifier noted that its use added very strong data about the likelihood of patients with prostate cancer dying within 10 years.

Dr. Jim Hu on Reevaluating PSA and the PLCO Trial

May 19th 2016

Jim Hu, MD, MPH, director of the LeFrak Center for Robotic Surgery at NewYork-Presbyterian/Weill Cornell Medical Center and the Ronald Lynch Chair of Urologic Oncology at Weill Cornell Medical College, discusses critical flaws in the landmark PLCO trial in prostate cancer.

PD-1 Expression on Monocytes Potential Immunotherapy Biomarker in RCC

May 13th 2016

Mohammed Haseebuddin, MD, discusses results of a study which demonstrated that elevated preoperative classical monocyte PD-1 mean fluorescence intensity level and lower CM was linked to poor survival in patients with clear cell renal cell carcinoma, as well as the challenges with using PD-1 as a biomarker in these patients.

HIFU Demonstrates Significant Role in Prostate Cancer

May 13th 2016

Results of a multi-institutional prospective study showed that treatment with unilateral high-intensity focused ultrasound led to eradication of all clinically significant cancer in the treated lobe for 94% of patients with early prostate cancer.

Radium-223/Abiraterone Combo Improves QOL, Bone Pain in mCRPC

May 12th 2016

The combination of radium-223 dichloride (Xofigo) and abiraterone acetate (Zytiga) was associated with significant reductions in bone pain, as well as improvements in quality of life, in patients with metastatic castration-resistant prostate cancer.

Krishna Vanaja Donkena on Using Immune Markers to Predict Survival in Bladder Cancer

May 12th 2016

Krishna Vanaja Donkena, PhD, Assistant Professor of Biochemistry and Molecular Biology, Center for Individualized Medicine, Mayo Clinic, discusses using immune and checkpoint markers to predict cancer-specific survival in bladder cancer.

Task Force PSA Recommendation Challenged Following Analysis

May 11th 2016

Major health policy implications follow findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial, after it was found that 80% of the control group reported at least one PSA test during the trial.

Liquid Imiquimod Formulation May Induce Immune Response in Bladder Cancer

May 11th 2016

TMX-101 (Vesimune), a liquid formulation of the toll-like receptor 7 agonist imiquimod, appeared safe and demonstrated preliminary clinical activity, including the potential to induce an immune response, in patients with non-muscle invasive bladder cancer.